With the influence of living habits, eating habits and other factors, the incidence rate of diabetes has increased year by year. According to relevant research statistics, it is estimated that the incidence of type 2 diabetes will reach 438million in 2030, becoming a major disease endangering human life and health. Insulin resistance and secretion deficiency are the main pathogenesis of type 2 diabetes.

Relevant studies have shown that the probability of diabetes in obese people can be more than three times higher than that in normal people. Therefore, clinical intervention is mainly through drug intervention to control and correct central appetite, so as to improve insulin resistance. Dulaglutide is a common glucagon like peptide receptor agonist (GLP-1) analog in clinic, which can specifically bind with the receptor, promote insulin secretion, reduce glucagon secretion, and improve glucose metabolism

Studies have proved that Dula glycopeptide has no significant adverse effects on the body on the basis of regulating the level of glucose metabolism, and its safety is high. The reason for the analysis is that dulaglutide is a GLP-1 analog. When acting in the body, it can greatly inhibit the secretion of glucagon against the output of liver sugar, and promote the secretion of insulin. Through the strengthening of glucose utilization by peripheral cells, it can improve insulin resistance, and then have an inhibitory effect on central nervous appetite. On the basis of promoting the weight loss of patients, it can regulate the body protein Carbohydrate and fat metabolism.

When dulaglutide acts on the body of patients with type 2 diabetes, it will strengthen the central nervous system to a certain extent. It can reduce the local systolic blood pressure, so as to reduce the risk of cardiovascular disease. During the treatment of type 2 diabetes, the hypoglycemic effect of dulaglutide is mainly glucose concentration dependent. During the treatment, patients have no hypoglycemic events, only some nausea, vomiting, diarrhea Abdominal distension and other conditions, with mild symptoms, can disappear automatically with the extension of the treatment cycle, with high safety. Therefore, the treatment of type 2 diabetes patients with dulaglutide can reduce blood glucose levels and improve clinical symptoms.

---

From Omizzur biotech (www.omizzur.com)